On May 29, Innovent Biologics rose 9.15% in regular trading, trading at HKD 81.45/share, with trading volume of HKD 176 million. The surge was driven by the announcement of a landmark global strategic licensing and collaboration agreement with Pfizer.

According to the filing, the deal covers 12 oncology programs comprising eight Innovent-originated early-stage assets and four Pfizer-proposed discovery programs. Innovent will receive an upfront payment of $650 million and is eligible for up to $9.85 billion in development, regulatory, and commercial milestone payments, bringing total deal value to $10.5 billion. Commercialized products will earn double-digit percentage royalties. Innovent retains Greater China rights, while Pfizer receives exclusive licenses outside Greater China and will bear the majority of development costs. Four key programs will be co-developed globally.

The deal follows a difficult session on May 28, when Innovent fell over 3% amid sector-wide weakness and investor concerns over the company's $690 million structured note purchases. The Pfizer partnership significantly bolsters Innovent's global pipeline credibility and near-term cash position.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)